Helping the Fight against Hepatitis in China

Partnership objective

Bring state-of-the-art diagnostics testing and therapy to patients living with Hepititis B in China.

An integrated approach to the treatment of Hep B means the patient’s quality of life is enormously improved. An integrated approach to the treatment of Hep B means the patient’s quality of life is enormously improved. Copyright Roche

What are the health needs and challenges?

Of the 350 million people chronically infected with the hepatitis B virus (HBV) worldwide, around 100 million live in China. HBV is a main cause of chronic liver disease, cirrhosis, and primary liver cancer. People with hepatitis are often unaware of their infection or simply do not have access to treatment in China.

Description of partnership activities and how they address needs and challenges

In order to help this situation, Roche has established diagnostic capacity and medical training to improve know-how for wider access to correct treatment regimes. Diagnostics play a key role in developing targeted medicines and in combining drugs with sophisticated tests that assess whether a patient is likely to respond to treatment. Today, over 60% of new Roche compounds are developed in conjunction with a diagnostic test.

Both its Pharmaceuticals and Diagnostics Divisions work closely together to ensure the right treatment is offered to the right patient.

Given the prevalence of Hepatitis B in China, it is vital to identify those patient sub-groups most likely to benefit from a targeted therapy. As a result, more and more patients see improved outcomes. This integrated approach means the patient’s quality of life is enormously improved and resources are used optimally.

In China, Roche is piloting a number of differential pricing models in partnership with local NGOs and government organisations. The aim is to tailor prices to the needs of patients and healthcare providers across countries, and within population segments, based on their ability to pay. This program has seen the treatment Pegasys (for Hepatitis B and C), grow from reaching 8,000 patients in 2010 to reaching 14,000 patients in 2013.

Partnership information

Company(ies) Roche

Partner(s) China Foundation for Hepatitis Prevention and Control, Chinese Ministry of Health

Type of Partner(s) Government, NGOs

Therapeutic Focus Vaccine-Preventable Diseases

Disease(s) Hepatitis

Program Type(s) Availability of Treatment - Differential Pricing, Health System Infrastructure - Training, Prevention Programs - Awareness & Outreach, Research & Development - Operations Research

Targeted Population(s) Health professionals, Men, Patients in needs of treatment, Women

Region(s) East Asia & Pacific

Number of Countries 1

Country(ies) China

Start Date 2010

More information Roche Access to Healthcare

Anticipated completion date Ongoing

« The immediate combination of diagnosis, therapy and monitoring of treatment success in Hepatitis B infection is a major step forward. This increases the benefits for our patients enormously. »

Prof. Henry Lik-Yuen Chan, Director, Centre for Liver Health